ALBANY, N.Y.--(BUSINESS WIRE)--AMRI (NASDAQ:AMRI) today announced the selection of a compound from its proprietary obesity treatment research program for advanced preclinical testing, with the goal of submitting an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) in 2010.
